Sanna Hulkki-Wilson

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial

M. Cheang, D. Tu, L. Trusolino, 2020, JCO precision oncology.

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

M. Aresu, S. Chua, I. Chau, 2022, Current oncology.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial

M. Rugge, M. Fassan, M. Nankivell, 2017, JAMA oncology.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Andrea Sottoriva, Nina Tunariu, Paul Workman, 2018, Science.

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

A. Wotherspoon, D. Cunningham, C. Lord, 2019, European journal of cancer.

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

George D. Cresswell, M. Fassan, A. Sottoriva, 2020, Gut.